A new study from Case Western Reserve University in the US has raised concerns about NAD+ supplements, popular for boosting energy and promoting healthy ageing. The research suggests these supplements might negatively impact cancer treatments.
NAD+ supplements, including nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), are marketed to improve metabolism and cellular repair. While some cancer patients believe these could ease chemotherapy side effects, the study indicates they might inadvertently aid cancer cells.
Published in Cancer Letters, the study found that these supplements might help pancreatic cancer cells survive chemotherapy. Pancreatic cancer is one of the deadliest forms, with a low five-year survival rate, so treatment effectiveness is crucial.
NAD+ is essential for cell survival and function in both healthy and cancerous cells. The research showed that boosting NAD+ levels might strengthen cancer cells, enabling them to resist treatments like chemotherapy. This happens because the supplements increase energy production, lower oxidative stress, and limit DNA damage, making it harder for chemotherapy to work effectively.
Lead researcher Jordan Winter has urged caution in using NAD+ supplements alongside cancer treatments. While these might not harm healthy people, they could pose risks for cancer patients.
The study suggests routine screening for supplement use in cancer patients and calls for further research. Patients are advised to discuss any supplements with their oncologists.
